Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9658614 | 0.80 | FDPS (0.44) | SMN1; SMN2NPC1RAB9ATDP1MAPT | |
| SCHEMBL20536536 | 0.79 | FDPS (0.44) | PGK1PGK2MAPT | |
| SCHEMBL4848422 | 0.78 | PGK1 (0.44) | PGK1PGK2SLC6A3 | |
| SCHEMBL4134899 | 0.78 | PKM (0.45) | SMN1; SMN2NPC1RAB9ATDP1MAPT | |
| SCHEMBL25426497 | 0.77 | PGK1 (0.47) | PGK1PGK2SMN1; SMN2SLC6A3 | |
| SCHEMBL4847747 | 0.77 | PGK1 (0.43) | PGK1PGK2SMN1; SMN2ALDH1A1 | |
| SCHEMBL20536448 | 0.77 | PGK1 (0.43) | PGK1PGK2SMN1; SMN2 | |
| SCHEMBL4849187 | 0.77 | SLC6A3 (0.44) | PGK1PGK2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL20536453 | 0.76 | PGK1 (0.46) | PGK1PGK2 | |
| SCHEMBL1107431 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9ATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3609538-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | William Marsh Rice University (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191394-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-10-18 | — | — | WO | disclosed |
| US-9156877-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| WO-2015087351-A2 | PROCESS FOR THE PREPARATION OF (1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[(1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL]-17-OXA-4-AZABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE AND INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-06-18 | — | — | WO | disclosed |
| US-20120316145-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120258941-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | US | disclosed |
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | MORPHONCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | WOLFGANG RICHTER (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1567524-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | Richter, Wolfgang (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004048372-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | MORPHOCHEM AG KOMB CHEMIE (DE) | 2004-06-10 | — | — | WO | disclosed |
| US-6156905-A | Deoxy epothilones and intermediates utilized in the process for preparing epothilones | NOVARTIS AG (CH) | 2000-12-05 | — | — | US | disclosed |
| US-6043372-A | USEFUL CHEMICAL INTERMEDIATES FOR ANTICARCINOGENIC EPITHILONES | NOVARTIS AG (CH) | 2000-03-28 | — | — | US | disclosed |
| US-5969145-A | Process for the production of epothilones and intermediate products within the process | NOVARTIS AG (CH) | 1999-10-19 | — | — | US | disclosed |
| EP-0923583-A1 | METHOD FOR PRODUCING EPOTHILONES, AND INTERMEDIATE PRODUCTS OBTAINED DURING THE PRODUCTION PROCESS | Novartis AG (CH) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008849-A1 | METHOD FOR PRODUCING EPOTHILONES, AND INTERMEDIATE PRODUCTS OBTAINED DURING THE PRODUCTION PROCESS | NOVARTIS AKTIENGESELLSCHAFT (CH) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | TTPA, THPO, TERT | PGK1 1131/4885PGK2 1052/4885SMN1; SMN2 3924/4885 |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | CCNI, CCNB1, CCNC | PGK1 638/4885PGK2 581/4885SMN1; SMN2 3320/4885 |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | PGK1 4481/4885PGK2 3836/4885SMN1; SMN2 2194/4885 |
| US-20120258941-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | CYP19A1, SHBG, HSD17B11 | PGK1 3640/4885PGK2 3904/4885SMN1; SMN2 1517/4885 |
| US-20120316145-A1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | HSD17B11, CYP17A1, CYP19A1 | PGK1 3755/4885PGK2 3708/4885SMN1; SMN2 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.